Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC
PurposeTo investigate the impact of preoperative contrast-enhanced CT-based radiomics model on PD-1 prediction in hepatocellular carcinoma (HCC) patients.MethodsThe study included 105 HCC patients (training cohort: 72; validation cohort: 33) who underwent preoperative contrast-enhanced CT and receiv...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1435668/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582894021771264 |
|---|---|
| author | Gulizaina Hapaer Feng Che Qing Xu Qian Li Ailin Liang Zhou Wang Jituome Ziluo Xin Zhang Yi Wei Yuan Yuan Bin Song Bin Song |
| author_facet | Gulizaina Hapaer Feng Che Qing Xu Qian Li Ailin Liang Zhou Wang Jituome Ziluo Xin Zhang Yi Wei Yuan Yuan Bin Song Bin Song |
| author_sort | Gulizaina Hapaer |
| collection | DOAJ |
| description | PurposeTo investigate the impact of preoperative contrast-enhanced CT-based radiomics model on PD-1 prediction in hepatocellular carcinoma (HCC) patients.MethodsThe study included 105 HCC patients (training cohort: 72; validation cohort: 33) who underwent preoperative contrast-enhanced CT and received systemic sorafenib treatment after surgery. Radiomics score was built for each patient and was integrated with independent clinic radiologic predictors into the radiomics model using multivariable logistic regression analysis.ResultsSeventeen radiomics features were finally selected to construct the radiomics score. In multivariate analysis, serum creatine and peritumoral enhancement were significant independent factors for PD-1 prediction. The radiomics model integrated radiomics signature with serum creatine and peritumoral enhancement showed good discriminative performance (AUC of 0.897 and 0.794 in the training and validation cohort). Overall survival (OS) was significantly different between the radiomics-predicted PD-1-positive and PD-1-negative groups (OS: 29.66 months, CI:16.03-44.40 vs. 31.04 months, CI: 17.10-44.07, P<0.001). Radiomics-predicted PD-1 was an independent predictor of OS of patients treated with sorafenib after surgery. (Hazard ratio [HR]: 1.61 [1.23-2.1], P<0.001).ConclusionThe proposed model based on radiomic signature helps to evaluate PD-1 status of HCC patients and may be used for evaluating patients most likely to benefit from sorafenib as a potentially combination therapy regimen with immune checkpoint therapies. |
| format | Article |
| id | doaj-art-04dca89b35d04b639e6818ab7a9788be |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-04dca89b35d04b639e6818ab7a9788be2025-01-29T06:45:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.14356681435668Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCCGulizaina Hapaer0Feng Che1Qing Xu2Qian Li3Ailin Liang4Zhou Wang5Jituome Ziluo6Xin Zhang7Yi Wei8Yuan Yuan9Bin Song10Bin Song11Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaInstitute of Clinical Pathology, Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaPharmaceutical Diagnostics, General Electric (GE) Healthcare, Shanghai, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Radiology, Sanya People’s Hospital, Sanya, ChinaPurposeTo investigate the impact of preoperative contrast-enhanced CT-based radiomics model on PD-1 prediction in hepatocellular carcinoma (HCC) patients.MethodsThe study included 105 HCC patients (training cohort: 72; validation cohort: 33) who underwent preoperative contrast-enhanced CT and received systemic sorafenib treatment after surgery. Radiomics score was built for each patient and was integrated with independent clinic radiologic predictors into the radiomics model using multivariable logistic regression analysis.ResultsSeventeen radiomics features were finally selected to construct the radiomics score. In multivariate analysis, serum creatine and peritumoral enhancement were significant independent factors for PD-1 prediction. The radiomics model integrated radiomics signature with serum creatine and peritumoral enhancement showed good discriminative performance (AUC of 0.897 and 0.794 in the training and validation cohort). Overall survival (OS) was significantly different between the radiomics-predicted PD-1-positive and PD-1-negative groups (OS: 29.66 months, CI:16.03-44.40 vs. 31.04 months, CI: 17.10-44.07, P<0.001). Radiomics-predicted PD-1 was an independent predictor of OS of patients treated with sorafenib after surgery. (Hazard ratio [HR]: 1.61 [1.23-2.1], P<0.001).ConclusionThe proposed model based on radiomic signature helps to evaluate PD-1 status of HCC patients and may be used for evaluating patients most likely to benefit from sorafenib as a potentially combination therapy regimen with immune checkpoint therapies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1435668/fullhepatocellular carcinomaPD-1radiomicscomputed tomographyoverall survival |
| spellingShingle | Gulizaina Hapaer Feng Che Qing Xu Qian Li Ailin Liang Zhou Wang Jituome Ziluo Xin Zhang Yi Wei Yuan Yuan Bin Song Bin Song Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC Frontiers in Immunology hepatocellular carcinoma PD-1 radiomics computed tomography overall survival |
| title | Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC |
| title_full | Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC |
| title_fullStr | Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC |
| title_full_unstemmed | Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC |
| title_short | Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC |
| title_sort | radiomics based biomarker for pd 1 status and prognosis analysis in patients with hcc |
| topic | hepatocellular carcinoma PD-1 radiomics computed tomography overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1435668/full |
| work_keys_str_mv | AT gulizainahapaer radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT fengche radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT qingxu radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT qianli radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT ailinliang radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT zhouwang radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT jituomeziluo radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT xinzhang radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT yiwei radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT yuanyuan radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT binsong radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc AT binsong radiomicsbasedbiomarkerforpd1statusandprognosisanalysisinpatientswithhcc |